NICE approves eltrombopag for NHS use

on the 24 July 2013

NICE has ruled that eltrombopag (Revolade) can be considered for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (ITP) within its marketing authorisation, following a review of its 2010 guidance.

Eltrombopag is an oral thrombopoietin receptor agonist that increases platelet counts by stimulating the differentiation and proliferation of megakaryocytes | SCIENCE PHOTO LIBRARY
Eltrombopag is an oral thrombopoietin receptor agonist that increases platelet counts by stimulating the differentiation and proliferation of megakaryocytes | SCIENCE PHOTO LIBRARY

To be eligible for treatment, the patient must either be refractory to standard active treatments and rescue therapies or have severe ITP and a high risk of bleeding that needs frequent course of rescue therapies. 

The NICE recommendations are made on the proviso that the manufacturer provides eltrombopag with the discount agreed in the patient access scheme.

View Revolade drug record

NICE guidance on eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (review of technology appraisal 205).

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

The most up-to-date drug information at your fingertips.

  • Get the prescribing support you need.
  • Register today for full access to the MIMS database, plus tables and guideline summaries, new and deleted products and consultation tools.
Register Now
Already Registered?

Forgotten password?

MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Twitter  

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more